Drug intelligence / Profile preview

Tumor antigen-sensitized dendritic cell vaccine + sensitized T cells

Development stage: Unknown
Lead developer: MaxCyte
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous, Intradermal, Subcutaneous, Intranodal, Intratumoral

Overview

A personalized cancer immunotherapy approach that combines dendritic cells loaded with tumor antigens and sensitized T cells. The dendritic cells present tumor antigens to the immune system, activating T cells to target and destroy cancer cells. This dual approach aims to enhance anti-tumor immune responses.

Other names: DCVax-LDendritic cell vaccination

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on Tumor antigen-sensitized dendritic cell vaccine + sensitized T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor antigen-sensitized dendritic cell vaccine + sensitized T cells.

Explore the full profile